- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Alembic Pharmaceuticals launches adapalene gel for acne vulgaris
Author(s):
Alembic Pharmaceuticals announces the launch of their bioequivalent and therapeutically equivalent product to Differin Gel 0.3% (Galderma), Adapalene Gel USP 0.3%, a topical retinoid for the treatment of acne vulgaris in patients 12 years and older.
Adapalene Gel USP 0.3% (Alembic Pharmaceuticals), a bioequivalent and therapeutically equivalent to Galderma’s Differin Gel 0.3% (Adapalene), has launched in the United States, according to manufacturer Alembic Pharmaceuticals.
Adapalene Gel USP 0.3% is indicated for the treatment of acne in patients ages 12 years and older. The topical treatment will be available in a 45 mg gel tube, as well as a 45 mg gel pump, the company says.
MORE: FDA approves Aleor’s adapalene gel for acne vulgaris
The abbreviated new drug application (ANDA) for the topical retinoid was approved by the U.S. Food and Drug Administration (FDA) in June 2020. This is the 65th product launch from Alembic since its introduction of U.S. operations in October 2015.
More information about Adapalene Gel USP 0.3% and other Alembic products can be found at www.alembicusa.com.
References:
1. Alembic Pharmaceuticals, PR. (2020, August 27). Adapalene Gel, 0.3% Tube and Pump - Press Release [Press release]. Retrieved August 31, 2020.
